分子癌症诊断市场：按癌症类型、产品类型和地理划分的市场预测，附高级顾问指南，以及人工智慧的影响（2026-2030）

报告概述

分子癌症诊断重回成长轨道，所有细分市场均呈现加速成长态势。本报告特别关注癌症伴随诊断，这是一个正在重塑产业的新兴细分市场。报告介绍了超过140家公司。各种动态趋势正在推动市场成长和公司估值。

例如，以下趋势：

• 个人化医疗
• 药物基因组学
• 液体活检
• 微小残留疾病检测
• 拥有庞大市场的新经济体的崛起
• 基于医生的诊断正被新的智慧诊断测试所取代

令人兴奋的技术发展，尤其是在伴随诊断领域，预示着一个充满活力、不断增长和演变的全球市场的到来，在这个市场中，一个实验室可以为全球患者提供服务。

此外，我们的报告还包含免费的客製化、细分、协助和支援。

针对新技术测试的特定成长和市场规模估算的支援通常免费提供。现有的实验室和医院可以直接使用这些资讯来预测和规划其临床成长。此类资讯的支援通常也免费提供。

本报告包​​含18个国家/地区和4个地区的详细分类。购买本报告的用户还将获得全球任何国家的详细分类。

目录

第1章 市场指南

第2章 简介与市场定义

• 什么是分子诊断？
• 诊断革命
• 市场定义
• 研究方法
• 视角：医疗保健支出

第3章 市场概要

• 市场区隔
• 产业结构

第4章 市场趋势

• 成长促进因素
  • 新诊断方法创造新市场
  • 诊断的新角色
  • 老化的影响
  • 扩充製药工具箱
  • 监理撤销
• 成长限制
  • 价格下跌
  • 成本降低
  • 健康也有弊端
• 测量、自动化和诊断的趋势
  • 传统自动化和集中化
  • 新型自动化、分散化与即时诊断
  • 设备是市占率的关键
  • 生物资讯学发挥重要作用
  • PCR 占领先地位
  • 新一代定序技术推动变革
  • NGS 的价格影响
  • 全基因组定序，一个美丽新世界
  • 伴随诊断模糊了诊断与治疗之间的界限
  • 诊断的作用不断变化
  • 多重分析与 Foundation One
  • 药物基因体学技术
  • 基因编辑与基因治疗

第5章 分子诊断的最近趋势

第6章 分子诊断的主要企业简介

• 10x Genomics, Inc.
• Abbott Laboratories
• AccuraGen Inc.
• Acuamark Diagnostics
• Adaptive Biotechnologies
• Admera Health, LLC
• Aethlon Medical
• Agilent
• Amoy Diagnostics Co., Ltd.
• Anchor Dx
• ANGLE plc
• ARUP Laboratories
• AVIVA Systems Biology
• Baylor Miraca Genetics Laboratories
• Beckman Coulter Diagnostics(Danaher)
• Becton, Dickinson and Company
• BGI Genomics Co. Ltd
• BillionToOne
• Bioarray Genetics
• Biocartis
• Biocept, Inc.
• Biodesix Inc.
• BioFluidica
• BioGenex
• BioIVT
• Biolidics Ltd
• bioMerieux Diagnostics
• Bioneer Corporation
• Bio-Rad Laboratories, Inc
• Bio-Reference Laboratories
• Bio-Techne
• Bioview
• Bristol-Myers Squibb
• Burning Rock
• C2i Genomics
• Cardiff Oncology
• Caris Molecular Diagnostics
• Castle Biosciences, Inc.
• Celemics
• CellCarta
• CellMax Life
• Cepheid(Danaher)
• Charles River Laboratories
• Circulogene
• Cizzle Biotech
• Clearbridge Biomedics
• Clinical Genomics
• Cytolumina Technologies Corp.
• Datar Cancer Genetics Limited
• Diagnologix LLC
• Diasorin S.p.A.
• Dxcover
• Element Biosciences
• Enzo Biochem
• Epic Sciences
• Epigenomics AG
• Erythra
• Eurofins Scientific
• Exact Sciences
• Fabric Genomics
• Fluxion Biosciences(Cell Microsystems)
• Freenome
• FUJIFILM Wako Diagnostics
• Fujirebio
• Fulgent Genetics
• Fyr Diagnostics
• GeneDx Holdings
• GeneFirst Ltd.
• Genetron Holdings
• GenomOncology
• GILUPI Nanomedizin
• Guardant Health
• HansaBiomed
• HTG Molecular Diagnostics
• iCellate
• ICON PLC
• Illumina
• Incell Dx
• Inivata
• INOVIQ
• Invitae Corporation
• Invivogen
• Invivoscribe
• J&J Innovative Medicine
• Lucence Health
• Lucid Diagnostics
• Lunglife AI Inc
• MDNA Life SCIENCES, Inc.
• MDx Health
• Menarini Silicon Biosystems
• Mesa Laboratories, Inc.
• Metabiomics Corp
• Millipore Sigma
• Miltenyi Biotec
• miR Scientific
• Myriad Genetics
• Nanostring
• NantHealth, Inc.
• Natera
• NeoGenomics
• NGeneBio
• Novogene
• Oncimmune
• Oncocyte
• OncoDNA
• Oncohost
• OraLiva
• Oxford Nanopore Technologies
• PamGene
• Panagene
• Personalis
• Perthera
• PGDx(Labcorp)
• Precipio
• PrecisionMed
• Predicine
• Predictive Oncology
• Prenetics
• Promega
• Qiagen
• QuidelOrtho
• Rarecells SAS
• RareCyte
• Revvity
• Roche Diagnostics
• S2 Genomics
• Screencell
• Sherlock Biosciences
• Siemens Healthineers
• simfo GmbH
• Singlera Genomics Inc.
• Singular Genomics
• Singulomics
• SkylineDx
• Standard BioTools
• Stemcell Technologies
• Stilla Technologies
• Sysmex Inostics
• Tempus Labs, Inc.
• Thermo Fisher Scientific
• Todos Medical
• Ultima Genomics
• Variantyx
• Vela Diagnostics
• Veracyte
• VolitionRX
• Vortex Biosciences
• Zhejiang Orient Gene Biotech

第7章 全球癌症的分子诊断市场

• 癌症的分子诊断-全球市场概要，各国
• 全球市场- 概要，各癌症类型
• 全球市场- 概要，各产品类型
• 全球市场- 概要，各地区

第8章 全球市场，各癌症类型

• 乳癌
• 大肠癌症
• 子宫颈癌症
• 肺癌症
• 前列腺癌症
• 黑色素瘤癌症
• 血液癌症
• 伴随式诊断的发展
• 其他

第9章 全球市场，各产品类型

• 设备
• 试剂
• 软体及服务

第10章 全球市场，各场所

• 临床检验室
• 製药公司
• 研究

第11章 癌症治疗和临床试验

• FDA核准(各年度·各用途)
• 临床试验开始
• 癌症治疗的普及率

第12章 附录

Report Overview:

Cancer Molecular Diagnostics is back on the growth path. And growth is accelerating in every segment. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. Over 140 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.

Trends like ......

• personalized medicine
• pharmacogenomics
• liquid biopsy
• minimal residual disease testing
• emergence of new economies with large markets
• physician diagnostics being displaced by new intelligent diagnostic tests

Exciting technical developments especially in companion diagnostics, hold the promise of a dynamic, growing and evolving world market where single laboratories serve a global patient base.

In addition customization work, breakouts for particular segments, assistance and support is included free of charge with every report.

Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Table of Contents

1. Market Guides

• 1.1. Cancer MDx - Strategic Situation Analysis
• 1.2. Guide for Executives, Marketing, and Business Development Staff
• 1.3. Guide for Management Consultants and Investment Advisors
• 1.4. Impact of Artificial Intelligence on Cancer MDx

2. Introduction and Market Definition

• 2.1. What are Molecular Diagnostics?
• 2.2. The Diagnostics Revolution
• 2.3. Market Definition
  • 2.3.1. Revenue Market Size
• 2.4. Methodology
  • 2.4.1. Methodology
  • 2.4.2. Sources
  • 2.4.3. Authors
• 2.5. Perspective: Healthcare Spending
  • 2.5.1. Global Healthcare Spending
  • 2.5.2. Spending on Healthcare and Pharmaceuticals
  • 2.5.3. Spending on Diagnostics
  • 2.5.4. Important Role of Insurance for Medical Services

3. Market Overview

• 3.1. Market Segments
  • 3.1.1. Traditional Market Segmentation
  • 3.1.2. Laboratory Focus and Segmentation
• 3.2. Industry Structure
  • 3.2.1. Hospital Testing Share
  • 3.2.2. Economies of Scale
  • 3.2.3. Physician Office Lab's
  • 3.2.4. Physician's and POCT

4. Market Trends

• 4.1. Factors Driving Growth
  • 4.1.1. New Diagnostics Create New Markets
  • 4.1.2. New Roles for Diagnostics
  • 4.1.3. Aging Effect
  • 4.1.4. Expanding the Pharmaceutical Toolbox
  • 4.1.5. Regulatory Retreat
• 4.2. Factors Limiting Growth
  • 4.2.1. Falling Prices
  • 4.2.2. Lower Costs
  • 4.2.3. Wellness has a Downside
• 4.3. Instrumentation, Automation and Diagnostic Trends
  • 4.3.1. Traditional Automation and Centralization
  • 4.3.2. The New Automation, Decentralization and Point Of Care
  • 4.3.3. Instruments Key to Market Share
  • 4.3.4. Bioinformatics Plays a Role
  • 4.3.5. PCR Takes Command
  • 4.3.6. Next Generation Sequencing Fuels a Revolution
  • 4.3.7. NGS Impact on Pricing
  • 4.3.8. Whole Genome Sequencing, A Brave New World
  • 4.3.9. Companion Diagnostics Blurs Diagnosis and Treatment
  • 4.3.10. Shifting Role of Diagnostics
  • 4.3.11. Multiplexing and Foundation One
  • 4.3.12. Pharmacogenomics Technology
  • 4.3.13. Gene Editing and Gene Therapy

5. Molecular Diagnostics Recent Developments

• 5.1. Recent Developments - Importance and How to Use This Section
  • 5.1.1. Importance of These Developments
  • 5.1.2. How to Use This Section
• 5.2. Biodesix Revenues up
• 5.3. Waters to buy Becton unit
• 5.4. QuidelOrtho refocuses with LEX acquisition
• 5.5. Guardant Health Guardant360 Tissue
• 5.6. AccuStem Sciences & EmeritusDx partner for Lung Cancer Screening
• 5.7. LetsGetChecked LaunchesHereditary Cancer Test
• 5.8. Guardant Health's Colorectal Test New Status
• 5.9. Tempus xT CDx
• 5.10. OneCell Diagnostics Raises $16M
• 5.11. A. Menarini to use Nucleix Bladder Cancer Test
• 5.12. Foundation Medicine, Repare Therapeutics to Develop CDx
• 5.13. NHS Declines to Accelerate Grail Galleri Implementation
• 5.14. GeneDx Sees Growing Demand for Testing
• 5.15. Thermo Fisher and Bayer to Develop CDx for Cancer Therapies
• 5.16. ClearNote Health Expands Into Immunotherapy Monitoring
• 5.17. Foundation Medicine to Collaborate on CDx for Lung Cancer
• 5.18. Qiagen and Myriad Genetics Partner to Develop Cancer CDx
• 5.19. Lung Cancer Data Heralds Shift for Hummingbird Dx
• 5.20. PamGene Awarded Euro-7.5M for Immunotherapy Test
• 5.21. Grail Cancer Test Faces New Clinical Questions
• 5.22. Freenome Acquires Cancer Dx Firm Oncimmune
• 5.23. Quest Diagnostics to Acquire Liquid Biopsy Firm Haystack Oncology
• 5.24. Ultima Genomics, Genome Insight Partner on WGS for Cancer Patients
• 5.25. Digital Pathology Meets Cancer Sequencing
• 5.26. Exact Sciences Preps Expanded Oncology Portfolio
• 5.27. Qiagen Details Oncology Plans for Digital PCR Platform
• 5.28. Sema4 Exiting Reproductive Health Screening
• 5.29. Thermo Fisher Introduces Cancer Profiling Assay
• 5.30. Genomic Test IDs Cysts Likely to Progress to Cancer
• 5.31. Naveris to Commercialize Virus-Related Cancer Tests
• 5.32. Larger Liquid Biopsy Panels Loom
• 5.33. Halo Diagnostics to Offer Genomic Profiling Tests
• 5.34. BillionToOne Raises $125M
• 5.35. Local Cancer Genomic Profiling Options Grow
• 5.36. German MDx Firm Mainz Biomed Raises $10M in IPO
• 5.37. Guardant Health Q3 Revenues Up 27 Percent
• 5.38. BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection
• 5.39. Nucleix to Invest in Early-Stage Lung Cancer Dx
• 5.40. Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics
• 5.41. Grail Gets Approval for Galleri Multicancer Test
• 5.42. Finnish Firms to Form Point-of-Care Testing Firm
• 5.43. Datar Cancer Genetics Expands to Dx and Screening
• 5.44. HTG Molecular Diagnostics: HTG Transcriptome Panel
• 5.45. PacBio's Omniome Acquisition Shortens Path to Clinical
• 5.46. Invitae to Acquire Genosity for $200M
• 5.47. Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test
• 5.48. Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience
• 5.49. Natera Revenues Grow 35 Percent
• 5.50. AnchorDx Closes $40M Financing Round
• 5.51. Exact Sciences Strategy for End-to-End Cancer Testing
• 5.52. Genomics England: Whole Genome Sequencing for Cancer Patients to Launch

6. Profiles of Key MDx Companies

• 6.1. 10x Genomics, Inc.
• 6.2. Abbott Laboratories
• 6.3. AccuraGen Inc.
• 6.4. Acuamark Diagnostics
• 6.5. Adaptive Biotechnologies
• 6.6. Admera Health, LLC
• 6.7. Aethlon Medical
• 6.8. Agilent
• 6.9. Amoy Diagnostics Co., Ltd.
• 6.10. Anchor Dx
• 6.11. ANGLE plc
• 6.12. ARUP Laboratories
• 6.13. AVIVA Systems Biology
• 6.14. Baylor Miraca Genetics Laboratories
• 6.15. Beckman Coulter Diagnostics (Danaher)
• 6.16. Becton, Dickinson and Company
• 6.17. BGI Genomics Co. Ltd
• 6.18. BillionToOne
• 6.19. Bioarray Genetics
• 6.20. Biocartis
• 6.21. Biocept, Inc.
• 6.22. Biodesix Inc.
• 6.23. BioFluidica
• 6.24. BioGenex
• 6.25. BioIVT
• 6.26. Biolidics Ltd
• 6.27. bioMerieux Diagnostics
• 6.28. Bioneer Corporation
• 6.29. Bio-Rad Laboratories, Inc
• 6.30. Bio-Reference Laboratories
• 6.31. Bio-Techne
• 6.32. Bioview
• 6.33. Bristol-Myers Squibb
• 6.34. Burning Rock
• 6.35. C2i Genomics
• 6.36. Cardiff Oncology
• 6.37. Caris Molecular Diagnostics
• 6.38. Castle Biosciences, Inc.
• 6.39. Celemics
• 6.40. CellCarta
• 6.41. CellMax Life
• 6.42. Cepheid (Danaher)
• 6.43. Charles River Laboratories
• 6.44. Circulogene
• 6.45. Cizzle Biotech
• 6.46. Clearbridge Biomedics
• 6.47. Clinical Genomics
• 6.48. Cytolumina Technologies Corp.
• 6.49. Datar Cancer Genetics Limited
• 6.50. Diagnologix LLC
• 6.51. Diasorin S.p.A.
• 6.52. Dxcover
• 6.53. Element Biosciences
• 6.54. Enzo Biochem
• 6.55. Epic Sciences
• 6.56. Epigenomics AG
• 6.57. Erythra
• 6.58. Eurofins Scientific
• 6.59. Exact Sciences
• 6.60. Fabric Genomics
• 6.61. Fluxion Biosciences (Cell Microsystems)
• 6.62. Freenome
• 6.63. FUJIFILM Wako Diagnostics
• 6.64. Fujirebio
• 6.65. Fulgent Genetics
• 6.66. Fyr Diagnostics
• 6.67. GeneDx Holdings
• 6.68. GeneFirst Ltd.
• 6.69. Genetron Holdings
• 6.70. GenomOncology
• 6.71. GILUPI Nanomedizin
• 6.72. Guardant Health
• 6.73. HansaBiomed
• 6.74. HTG Molecular Diagnostics
• 6.75. iCellate
• 6.76. ICON PLC
• 6.77. Illumina
• 6.78. Incell Dx
• 6.79. Inivata
• 6.80. INOVIQ
• 6.81. Invitae Corporation
• 6.82. Invivogen
• 6.83. Invivoscribe
• 6.84. J&J Innovative Medicine
• 6.85. Lucence Health
• 6.86. Lucid Diagnostics
• 6.87. Lunglife AI Inc
• 6.88. MDNA Life SCIENCES, Inc.
• 6.89. MDx Health
• 6.90. Menarini Silicon Biosystems
• 6.91. Mesa Laboratories, Inc.
• 6.92. Metabiomics Corp
• 6.93. Millipore Sigma
• 6.94. Miltenyi Biotec
• 6.95. miR Scientific
• 6.96. Myriad Genetics
• 6.97. Nanostring
• 6.98. NantHealth, Inc.
• 6.99. Natera
• 6.100. NeoGenomics
• 6.101. NGeneBio
• 6.102. Novogene
• 6.103. Oncimmune
• 6.104. Oncocyte
• 6.105. OncoDNA
• 6.106. Oncohost
• 6.107. OraLiva
• 6.108. Oxford Nanopore Technologies
• 6.109. PamGene
• 6.110. Panagene
• 6.111. Personalis
• 6.112. Perthera
• 6.113. PGDx (Labcorp)
• 6.114. Precipio
• 6.115. PrecisionMed
• 6.116. Predicine
• 6.117. Predictive Oncology
• 6.118. Prenetics
• 6.119. Promega
• 6.120. Qiagen
• 6.121. QuidelOrtho
• 6.122. Rarecells SAS
• 6.123. RareCyte
• 6.124. Revvity
• 6.125. Roche Diagnostics
• 6.126. S2 Genomics
• 6.127. Screencell
• 6.128. Sherlock Biosciences
• 6.129. Siemens Healthineers
• 6.130. simfo GmbH
• 6.131. Singlera Genomics Inc.
• 6.132. Singular Genomics
• 6.133. Singulomics
• 6.134. SkylineDx
• 6.135. Standard BioTools
• 6.136. Stemcell Technologies
• 6.137. Stilla Technologies
• 6.138. Sysmex Inostics
• 6.139. Tempus Labs, Inc.
• 6.140. Thermo Fisher Scientific
• 6.141. Todos Medical
• 6.142. Ultima Genomics
• 6.143. Variantyx
• 6.144. Vela Diagnostics
• 6.145. Veracyte
• 6.146. VolitionRX
• 6.147. Vortex Biosciences
• 6.148. Zhejiang Orient Gene Biotech

7. The Global Market for MDx Cancer

• 7.1. MDx Cancer - Global Market Overview by Country
  • 7.1.1. Table - Global Market by Country
  • 7.1.2. Chart - Global Market by Country
• 7.2. Global Market by Cancer Type - Overview
  • 7.2.1. Table - Global Market by Cancer Type
  • 7.2.2. Chart - Global Market by Cancer Type - Base/Final Comparison
  • 7.2.3. Chart - Global Market by Cancer Type - Base Year
  • 7.2.4. Chart - Global Market by Cancer Type -Final Year
  • 7.2.5. Chart - Global Market by Cancer Type - Share by Year
  • 7.2.6. Chart - Global Market by Cancer Type - Segment Growth
• 7.3. Global Market by Product Type - Overview
  • 7.3.1. Table - Global Market by Product Type
  • 7.3.2. Chart - Global Market by Product Type - Base/Final Comparison
  • 7.3.3. Chart - Global Market by Product Type - Base Year
  • 7.3.4. Chart - Global Market by Product Type -Final Year
  • 7.3.5. Chart - Global Market by Product Type - Share by Year
  • 7.3.6. Chart - Global Market by Product Type - Segment Growth
• 7.4. Global Market by Place - Overview
  • 7.4.1. Table - Global Market by Place
  • 7.4.2. Chart - Global Market by Place - Base/Final Comparison
  • 7.4.3. Chart - Global Market by Place - Base Year
  • 7.4.4. Chart - Global Market by Place -Final Year
  • 7.4.5. Chart - Global Market by Place - Share by Year
  • 7.4.6. Chart - Global Market by Place - Segment Growth

8. Global Market by Cancer Type

• 8.1. MDx Breast Cancer
  • 8.1.1. Table Breast Cancer Testing - by Country
  • 8.1.2. Chart - Breast Cancer Testing Growth
• 8.2. MDx Colorectal Cancer
  • 8.2.1. Table Colorectal Cancer Testing - by Country
  • 8.2.2. Chart - Colorectal Cancer Testing Growth
• 8.3. MDx Cervical Cancer
  • 8.3.1. Table Cervical Cancer Testing - by Country
  • 8.3.2. Chart - Cervical Cancer Testing Growth
• 8.4. MDx Lung Cancer
  • 8.4.1. Table Lung Cancer Testing - by Country
  • 8.4.2. Chart - Lung Cancer Testing Growth
• 8.5. MDx Prostate
  • 8.5.1. Table Prostate Testing - by Country
  • 8.5.2. Chart - Prostate Testing Growth
• 8.6. MDx Melanoma Cancer
  • 8.6.1. Table Melanoma Cancer Testing - by Country
  • 8.6.2. Chart - Melanoma Cancer Testing Growth
• 8.7. MDx Blood
  • 8.7.1. Table Blood Testing - by Country
  • 8.7.2. Chart - Blood Testing Growth
• 8.8. MDx Companion Dx Development
  • 8.8.1. Table Companion Dx Development - by Country
  • 8.8.2. Chart - Companion Dx Development Growth
• 8.9. MDx Other Cancer
  • 8.9.1. Table Other Cancer Testing - by Country
  • 8.9.2. Chart - Other Cancer Testing Growth

9. Global Market by Product Type

• 9.1. MDx Instruments
  • 9.1.1. Table Instruments - by Country
  • 9.1.2. Chart - Instruments Growth
• 9.2. MDx Reagents
  • 9.2.1. Table Reagents - by Country
  • 9.2.2. Chart - Reagents Growth
• 9.3. MDx Software and Services
  • 9.3.1. Table Software and Services - by Country
  • 9.3.2. Chart - Software and Services Growth

10. Global Market by Place

• 10.1. MDx Clinical Laboratory
  • 10.1.1. Table Clinical Laboratory - by Country
  • 10.1.2. Chart - Clinical Laboratory Growth
• 10.2. MDx Pharmaceutical
  • 10.2.1. Table Pharmaceutical - by Country
  • 10.2.2. Chart - Pharmaceutical Growth
• 10.3. MDx Research
  • 10.3.1. Table Research - by Country
  • 10.3.2. Chart - Research Growth

11. Cancer Treatment and Trials

• 11.1. FDA Approvals by Year and Application
• 11.2. Clinical Trials Starts
• 11.3. Prevalence of Cancer Treatments

12. Appendices

• 12.1. United States Medicare System: Clinical Laboratory Fees Schedule
• 12.2. The Most Used IVD Assays
• 12.3. The Highest Grossing Assays
• 12.4. FDA Approved Human Genetic Tests
• 12.5. FDA Approved Pharmacogenomics Tests

Table of Tables

• Table 1: Clinical Laboratory Departments and Segments
• Table 2: Laboratory Management Focus - Different Approaches
• Table 3: Key Segmentation Variables Going Forward
• Table 4: Five Factors Driving Growth
• Table 5: Factors Limiting Growth
• Table 6: Seven Key Diagnostic Laboratory Technology Trends
• Table 7: Global MDx Cancer Market by Region
• Table 8: Global Market by Cancer Type
• Table 9: Global Market by Product Type
• Table 10: Global Market by Place
• Table 11: MDx Breast Cancer by Country
• Table 12: MDx Colorectal Cancer by Country
• Table 13: Cervical Cancer Testing by Country
• Table 14: Lung Cancer Testing by Country
• Table 15: Prostate Testing by Country
• Table 16: Melanoma Cancer Testing by Country
• Table 17: MDx Blood by Country
• Table 18: MDx Companion Dx Development by Country
• Table 19: MDx Other Cancer Testing by Country
• Table 20: MDx Instruments by Country
• Table 21: MDx Reagents by Country
• Table 22: Software and Services by Country
• Table 23: MDx Clinical Laboratory by Country
• Table 24: MDx Pharmaceutical by Country
• Table 25: Research by Country
• Table 26: Clinical Lab Fee Schedule
• Table 27: The Most Common Assays
• Table 28: Largest Revenue Assays

Table of Figures

• Figure 1: Global Healthcare Spending
• Figure 2: The Changing Age of The World's Population
• Figure 3: Health Care Consumption by Age
• Figure 4: Cancer Incidence - Age at Diagnosis
• Figure 5: Centralized vs. Decentralized Laboratory Service
• Figure 6: A Highly Multiplexed Syndromic Testing Unit
• Figure 7: The Real Cost to Sequence the Human Genome
• Figure 8: The Codevelopment Process
• Figure 9: Comparing MDx Diagnostic and Traditional Testing
• Figure 10: Global Market Shares Base Year
• Figure 11: MDx Market by Cancer - Base vs. Final
• Figure 12: Cancer Market Base Year
• Figure 13: Cancer Market Final Year
• Figure 14: MDx Cancer Share by Year
• Figure 15: MDx Cancer Segment Growth Rates
• Figure 16: MDx Market by Product - Base vs. Final
• Figure 17: Product Market Base Year
• Figure 18: Product Market Final Year
• Figure 19: MDx Product Share by Year
• Figure 20: MDx Product Segment Growth Rates
• Figure 21: MDx Market by Place - Base vs. Final
• Figure 22: Place Market Base Year
• Figure 23: Place Market Final Year
• Figure 24: MDx Place Share by Year
• Figure 25: MDx Place Segment Growth Rates
• Figure 26: Breast Cancer Testing Growth
• Figure 27: Colorectal Cancer Testing Growth
• Figure 28: Cervical Cancer Testing Growth
• Figure 29: Lung Cancer Testing Growth
• Figure 30: Prostate Testing Growth
• Figure 31: Melanoma Cancer Testing Growth
• Figure 32: Blood Testing Growth
• Figure 33: Companion Dx Development Growth
• Figure 34: Other Cancer Testing Growth
• Figure 35: Instruments Growth
• Figure 36: Reagents Growth
• Figure 37: Software and Services Growth
• Figure 38: Clinical Laboratory Growth
• Figure 39: Pharmaceutical Growth
• Figure 40: Research Growth
• Figure 41: FDA Approvals by Year and Application
• Figure 42: Clinical Trials for Oncology by Year
• Figure 43: Pie Chart of Prevalence of Cancer Treatments